Dr. Keith Flaherty is the director of the Henri and Belinda Termeer Center for Targeted Therapies. Dr. Flaherty and his exceptional team of clinicians and scientists are spearheading research into promising new treatment options for patients through phase I clinical investigation.
Three projects led by MGH investigators were named among the Clinical Research Forum’s Top 10 Clinical Research Achievements of 2012 at the organization’s annual meeting on April 18.
The Henri and Belinda Termeer Center for Targeted Therapies in the MGH Cancer Center has three new endowed leadership positions.
Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial.
Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma.
Three projects led by Massachusetts General Hospital (MGH) investigators have been named among the Clinical Research Forum's Top 10 Clinical Research Achievements of 2012.